Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

(2021) Hannah C. Timmins et al.   Journal of Cancer Survivorship

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

(2021) Tiffany M. Powell-Wiley et al.   CIRCULATION

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

(2021) L. Paz-Ares et al.   ESMO Open

Tropomyosin receptor kinase inhibitors: an updated patent review for 2016 – 2019

(2020) Justin J Bailey et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

Characterization of On-Target Adverse Events Caused by TRK Inhibitor Therapy

(2020) D. Liu et al.   ANNALS OF ONCOLOGY

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

(2020) Andrea Sartore-Bianchi et al.   Expert Review of Anticancer Therapy

Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†

(2020) B. Jordan et al.   ANNALS OF ONCOLOGY

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

(2020) Charles L. Loprinzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiemetics: ASCO Guideline Update

(2020) Paul J. Hesketh et al.   JOURNAL OF CLINICAL ONCOLOGY

Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study

(2019) D S Hong et al.   ANNALS OF ONCOLOGY

Larotrectinib: First Global Approval

(2019) Lesley J. Scott   DRUGS

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer

(2019) Noah Federman et al.   Expert Review of Clinical Pharmacology

TRK inhibitors in TRK fusion-positive cancers

(2019) A Drilon   ANNALS OF ONCOLOGY

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines†

(2018) P Bossi et al.   ANNALS OF ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

(2018) Shivaani Kummar et al.   Targeted Oncology

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma

(2017) Kate Fife et al.   Future Oncology

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer

(2016) K. N. Moore et al.   ONCOLOGIST

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

(2016) Mario E. Lacouture et al.   ONCOLOGIST

Guidance on the management of diarrhoea during cancer chemotherapy

(2014) Jervoise Andreyev et al.   LANCET ONCOLOGY

A systematic review of dysgeusia induced by cancer therapies

(2010) Allan J. Hovan et al.   SUPPORTIVE CARE IN CANCER

Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

(2009) Alexander Stein et al.   Therapeutic Advances in Medical Oncology